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Abstract 
  
 
	  
Background: Primary aldosteronism (PA) is the most common endocrine form of 
secondary arterial hypertension with an estimated prevalence of ~ 11.2% in 
patients referred to specialized centers and 4% in primary care, but as high as 50% 
in patients with resistant hypertension. The two main forms of PA are: 
aldosterone-producing adenoma (APA), surgically curable with the removal of 
adenoma that is able to overproduce aldosterone, and bilateral adrenocortical 
hyperplasia (BAH), which needs drug therapy. About ~ 30% APAs have somatic 
mutations in KCNJ5 gene that encodes for the potassium channel (KIR3.4), which 
plays a crucial role in the maintenance of the cell membrane by pumping  
potassium (K+) out of the cells, thereby producing a negative membrane potential. 
The KCNJ5 channels that contain G151R, T158A, or L168R mutations cause 
membrane permeability to Na+, resulting in Na+ entry, cell depolarization, 
constitutive aldosterone production, and cell proliferation.  
The standard approach used to detect the mutations in KCNJ5 gene is sequencing 
of DNA extracted from adrenal tissue of hypertensive patients with lateralized 
excess in aldosterone production. However, DNA sequencing is a time consuming 
and rather expensive technique not feasible in all standard laboratories.  
Aims of our study were 1) to develop a strategy for genotyping DNA extracted 
from the adrenal tissue, which exploited a TAQ-MAN based PCR technology; 2) 
to evaluate if such Taq-Man-base technology allows detection of KCNJ5 
mutations in the adrenal tissue and cf-DNA isolated from peripheral blood. 
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Methodologic Approach:  
 
1. Development of a novel strategy based on Taq-man probe to detect 
KCNJ5 mutations 
2. Development of a protocol to isolate cf-DNA from blood collected in the 
inferior vena cava and adrenal veins. 
3. Measurement of cf-DNA concentration and assessment of its 
fragmentation. 
4. Identification of KCNJ5 mutation in cf-DNA 
 
Results: By applying the novel technology based on Taq-man probe we correctly 
identified 30 mutated patients in a cohort of 50 consecutive APA patients, with no 
misclassification.  
After isolating cf-DNA from the adrenal veins and inferior cava blood, and 
measuring its concentration, we evaluated cf-DNA fragmentation with the 
integrity index in 24 samples. Integrity index < 1 suggested that cf-DNA was 
released from the adrenal tissue through an apoptotic mechanism. HRM analysis 
of cf-DNA isolated from adrenal blood allowed us to identify the KCNJ5 
mutation in the APA side.  
Conclusions and perspectives: The novel technology based on Taq-man probe 
allowed detection of  all mutated patients in the examined cohort of APA patients,  
thus proving that this strategy could be used as an alternative to DNA sequencing. 
The results of our study also showed the feasibility to isolate cf-DNA from small 
amount of blood collected from the adrenal veins, and suggested that KCNJ5 
mutations may be detected in cf-DNA. However, this approach needs to be 
verified for  feasibility and accuracy in a larger population. 
If confirmed, analysis of cf-DNA isolated from the peripheral venous blood could 
be helpful for an early detection of KCNJ5 mutations and therefore for the 
selection of PA patients to be submitted to adrenal vein sampling.  
Furthermore, this strategy could be also useful for detecting KCNJ5 germline 
mutations responsible for the rare hereditary form of hyperaldosteronism FH-3. 
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Riassunto 
 
	  
 
Background. L’Iperaldosteronismo primario (PA) è la forma endocrina 
più comune d’ipertensione arteriosa secondaria con una prevalenza stimata di 
circa il 4% nella popolazione generale e dell’11% nei pazienti che afferiscono ai 
centri di riferimento per l’ipertensione.  Nei pazienti con ipertensione resistente la 
prevalenza del PA è stimata pari al 50%, mostrando che tale patologia non è così 
rara come ritenuto in passato.  
Le due forme principali di PA sono l’adenoma producente aldosterone 
(APA), caratterizzato da iperproduzione lateralizzata di aldosterone, e l’iperplasia 
surrenalica bilaterale (BAH). La distinzione tra le due forme è di cruciale 
importanza poiché la prima richiede terapia chirurgica, mentre la seconda terapia 
medica. Considerando che la rimozione dell’APA determina la correzione del 
quadro biochimico-clinico di PA e la cura o il miglioramento dell’ipertensione, il 
riconoscimento dell’APA è fondamentale per offrire una chance di guarigione 
dell’ipertensione o di miglioramento del controllo dei valori pressori ai pazienti 
che ne sono affetti.  
Il 40% degli APA presenta mutazioni somatiche nel gene KCNJ5 che 
codifica per il canale del potassio KIR 3.4. Questo canale gioca un ruolo 
fondamentale nel mantenimento del potenziale di membrana pompando il K+ al di 
fuori della cellula, provocando in tal modo un potenziale di membrana negativo. 
Allorquando il gene KCNJ5 contiene le mutazioni G151R, T158A o L168R il 
canale KIR 3.4 acquisisce capacità di condurre Na+ all’interno della cellula. Gli 
effetti della mutazione a livello della cellula sono depolarizzazione cronica, 
produzione costitutiva di aldosterone e proliferazione cellulare.  
L’approccio attualmente in uso per identificare tali mutazioni è il 
sequenziamento, secondo Sanger, del DNA estratto dal tessuto surrenalico 
rimosso durante surrenectomia nei pazienti con PA e iperproduzione lateralizzata  
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di aldosterone. Il sequenziamento del DNA, tuttavia, è costoso , richiede tempo e 
non  è disponibile di routine in tutti i laboratori.  
Scopo generale dello studio è stato quello di sviluppare una strategia alternativa 
al sequenziamento fondata sull’uso delle sonde Taq-man in Real Time PCR (Q-
PCR) per il rilevamento di mutazioni KCNJ5 nel tessuto surrenalico e nel DNA 
circolante (cell-free DNA, cf-DNA) isolato da sangue periferico. Lo sviluppo di 
questa metodologia potrebbe semplificare notevolmente l’identificazione delle 
mutazioni KCNJ5 negli APA e, infine, permetterne la detezione nel DNA del 
sangue circolante.    
  
In sintesi, l’approccio metodologico include: 
 
sviluppo di una nuova strategia basata sull’utilizzo delle sonde Taq-man 
per rilevare le mutazioni nel gene KCNJ5. 
 
Sviluppo di un protocollo per isolare il cf-DNA da sangue delle vene 
surrenaliche e dalla vena cava inferiore. 
 
Misurazione della concentrazione del cf-DNA valutandone la sua 
frammentazione. 
 
Identificazione di mutazioni nel gene KCNJ5  a partire dal cf-DNA 
 
 
Risultati. Applicando la tecnologia sviluppata nel nostro laboratorio, basata sulle 
sonde Taq-man, sono stati identificati correttamente 30 pazienti mutati in una 
coorte di 50 pazienti APA consecutivi, senza errori di classificazione.  
Dopo aver isolato il cf-DNA dal sangue delle vene surrenaliche e dalla vena cava 
inferiore, e misurato la sua concentrazione, abbiamo valutato la frammentazione 
del cf-DNA in 24 campioni con l'indice di integrità.  
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I bassi valori dell’indice d’integrità riscontrati nei cf-DNA isolati da sangue 
venoso surrenalico suggeriscono che la ghiandola surrenalica rilasci per apoptosi  
frammenti di DNA. L’analisi HRM dei cf-DNA isolati dal sangue delle vene 
surrenaliche di un paziente con un APA sinistro contenente la mutazione L168R 
ha permesso d’identificare correttamente la mutazione nel cf-DNA isolato dalla 
vena surrenalica sinistra. 
Conclusioni e prospettive. La tecnologia basata sulle sonde Taq-man ha 
permesso d’identificare, senza errori di misclassificazione, in una coorte di 50 
pazienti con APA, tutti i 30 pazienti che presentano una mutazione del gene 
KCNJ5.  Tale strategia, pertanto, potrebbe rappresentare un’alternativa alla ben 
più lunga e complessa tecnica basata sul sequenziamento del DNA. I risultati del 
nostro studio hanno anche mostrato che è possibile isolare il cf-DNA da esigue 
quantità di sangue raccolto dalle vene surrenaliche permettendo l’identificazione 
delle mutazioni KCNJ5 usando il cf-DNA tramite approccio combinato sonde 
Taq-man e analisi HRM.  Quest’ultimo approccio,  che prevede l’uso del cf-DNA 
richiede, tuttavia, conferma in un ampio numero di soggetti. La stessa strategia 
potrebbe anche essere impiegata in futuro per la rilevazione di mutazioni 
germinali KCNJ5 responsabili della nota forma ereditaria d’iperaldosteronismo 
FH-3 
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Introduction 
	  
	  
Arterial hypertension (AH) affects 40% of the adult population  in Europe 
and 1 billion people worldwide. According to the Centers for Disease Control and 
Prevention (CDC) and PAN American Health Organization (PAHO) it is called 
the “silent killer” because most people often have no symptoms. 
Yet hypertension can lead to serious and sometimes even fatal conditions (Figure 
1). Hypertension is the first risk factor for cardiovascular disease and death 
throughout the world. In particular, AH can be divided into two main types based 
on its cause: primary and secondary forms. 
 
	  
 
	  
            Figure	  1:	  Prevalence	  of	  arterial	  hypertension	  in	  adult	  population	  (Data	  from	  Pan	  American	  
Health	  Organization/World	  Health	  Organization,	  PAHO/WHO,	  2013)	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Primary Hypertension	  
 
This term defines a condition in which physicians are not sure what are the 
causes of this common form of high blood pressure.  Primary hypertension is not 
directly attributable to any underlying condition, but it is caused by a combination 
of factors.  The upward resetting of heart, vessels, and barostat functions, as well 
as the occurrence of vascular remodelling, represent the most important long-term 
cardiovascular alterations that are responsible for the maintenance of AH (Folkow 
B. 1993).  
 
	  
	  
Secondary Hypertension 	  
 
 
The prevalence of these forms, where a precise mechanism responsible for 
the elevation of blood pressure can be found, is not precisely known, albeit it is 
quite obvious that these forms are markedly underdiagnosed.  These main forms 
are listed in figure 2.  
 
 
                    
Figure 2: The	  most	  common	  causes	  of	  secondary	  hypertension	  	  
from	  European	  Heart	  Journal	  2014	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Primary aldosteronism (PA) is the most common endocrine cause of secondary 
hypertension with an estimated prevalence of 11.2% in referred patients to the 
specialized centers and 4% in primary care (Rossi GP et Al. 2006). 
Prevalence is higher, up to 50%, in patients with resistant AH.  PA includes a 
variety of disorders characterized by an overproduction of aldosterone, the 
principal mineralocorticoid steroid hormone of family produced in the adrenal 
glands.  
  
Adrenal glands and aldosterone biosynthesis 
 
 
The adrenal glands are located bilaterally in the retro peritoneum superior and 
slightly medial to the kidney (Figure 3). Each adrenal gland is composed of two 
distinct structures: the adrenal cortex and medulla. The adrenal cortex is 
composed of three concentric layers: zona glomerulosa, zona fasciculata, and zona 
reticularis (Figure 4). They were originally described in 1866 by Arnold, and have 
different cellular differentiation that accounts for the specificity of the steroid 
production. 
 
               	  
                  
 Figure 3: Anatomy	  of	  Adrenal	  Gland	  
	  (From	  National	  Cancer	  Institute,	  Teresa	  Winslow	  2013)	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Figure 4: Adrenal	  Gland	  cross	  section	  	  
(From	  website	  Department	  of	  Physiology	  of	  Georgia)	  
 
 
 
The zona glomerulosa (ZG) lies just beneath the adrenal capsule and it is 
composed of small clusters containing less cytoplasm than the other cortical cells. 
The zona fasciculata (ZF) forms broad bands of large cells with distinct 
membranes arranged in cords of about two cells wide. Their cytoplasm has 
numerous small lipid vacuoles that may indent the central nucleus and resemble 
lipoblasts; most cortical volume and lipid stores are depleted after ACTH surge. 
The zona reticularis is composed of organized cells that are smaller and thinner 
than zona fasciculata cells, and contain granular, eosinophilic cytoplasm and 
abundant lipofuscin, but only scarce lipids.  
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Aldosterone is secreted by ZG cells (Figure 4). Its synthesis needs a series of 
specific enzymatic reactions, the final steps of which are catalyzed by aldosterone 
synthase (encoded by CYP11B2). The CYP11B2 gene shares a high degree of 
homology (95%) with the gene for 11 β-hydroxylase (CYP11B1), which catalyzes 
the final steps in cortisol biosynthesis in ZF (Figure 5). CYP11B1 and CYP11B2 
genes are located in tandem on chromosome 8q21–22 (McMahon GT, et al 2004). 
 
 
 
	  
	  
	  Figure	  5:	  Schematic	  Biosynthesis	  of	  Aldosterone	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The main aldosterone secretagogs are angiotensin II (Belloni et Al.1996), 
potassium (K+) and ACTH. In the basal state ZG cells are hyperpolarized (–78mV 
to –90 mV) because of background K+ leakage that occurs essentially via TWIK 
(tandem pore domain K+ channels), and in particular via TASK channels 1 and 3 
that are outwardly rectifying channels sensitive to changes in extracellular pH 
(Figure 6). (Carey et al. 2012, Velarde-Miranda et al, 2013). Binding of 
angiotensin II to angiotensin II subtype 1 receptor (AT1R) blocks these leaky 
channels and other K+ channels such as Kir3.4, as well as Na+/K+ ATPase, thus 
leading to glomerulosa membrane depolarization, activation of voltage-gated 
calcium channels (essentially low-voltage activated channels but also high-voltage 
activated channels) and calcium influx. Calcium is also released from intracellular 
stores via activation of phospholipase C (Hattangady NG et Al, 2012). Changes in 
extracellular K+ can also directly cause membrane depolarization and calcium 
entry (Beuschlein F et Al 2013). Intracellular calcium stimulates aldosterone 
production by acting at multiple steps (Guagliardo NA, et Al. 2012) by increasing: 
 
 
1. The activity of cholesterol ester hydrolase, which de-esterifies cholesterol 
and thus releases it from its cytoplasmic storage sites. 
 
2. The delivery of cholesterol to the outer mitochondrial membrane. 
 
 
3. The transcription and translation of steroidogenic acute regulator protein 
(StAR), which in turn increases the intra-mitochondrial transfer of 
cholesterol to the inner membrane. 
 
4. The mitochondrial oxidative metabolism and formation of the cofactors 
required for CYP11B2 activity, which in turn enhance the transcription of 
aldosterone synthase (Bassett MH et Al. 2004). 
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Figure	  6:	   	  A	  simplified,	  schematic	  diagram	  of	  a	  ZG	  cell	  at	  rest,	  when	  the	  cell	   is	  hyperpolarized	  
due	  to	  leaky	  K+	  channels	  (TASK).	  Both	  Na+/K+	  ATPase	  and	  Kir3.4	  contribute	  to	  the	  maintenance	  of	  
membrane	   hyperpolarization.	   The	   voltage-­‐gated	   Ca2+	   channels	   are	   represented	   in	   the	   closed	  
form.	  (The	  Application	  of	  Clinical	  Genetics	  2014)	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History of Primary Aldosteronism (PA) 
  
Dr. Jerome Conn was the first to well characterize the disorder (Coon and Louis, 
1956) after a case report by Litynski in 1953 in a polish journal (Litynski, 1953).  
Conn presented the first case of PA during his presidential address at the Annual 
Meeting of the Central Society for Clinical Research in October 1954. Six months 
earlier Dr. Stefan Fajans asked to Dr. Conn to evaluate a 34-year-old woman with 
a 7-year history of muscle spasms, weakness, episodic paralysis and tetany, who 
was hypertensive for at least 4 years. Conn suspected, based on his prior research 
in sodium balance and acclimatization to tropical weather, which the patient 
suffered from excess production of the adrenal salt-retaining hormone. He found 
that her sweat chloride was essentially undetectable, supporting his hypothesis. 
Although Conn planned a bilateral adrenalectomy, the surgeon William Baum 
removed the right adrenal gland where a 13g tumor was found. After surgery, the 
metabolic and clinical abnormalities reversed almost completely. Conn could 
therefore establish a link between the autonomous overproduction of aldosterone 
released from the tumor and the symptoms complained by the patient. Since then, 
the syndrome has been termed Conn’s syndrome (Rossi et Al. 2008) and the 
tumor producing excess aldosterone was defined as ‘Conn’s adenoma’, a form 
that was replaced by used as synonym of aldosterone-producing adenoma (APA). 
The inappropriate production of aldosterone in PA causes suppression of plasma 
renin, Na+ retention, K+ excretion, and high blood pressure. However, due to a 
reset osmostat, serum sodium concentration tends to be high normal or slightly 
high in most PA patients, which is a useful clinical clue in PA. With time excess 
aldosterone levels also cause hypomagnesaemia and metabolic alkalosis. If 
severe, PA associated hypokalemia induces development of weakness, myalgias, 
muscle spasms, headaches, and arrhythmias. Less frequently, decreased ionized 
calcium and hypokalemic metabolic alkalosis cause overt tetany, as in Conn’s 
index patient.  
 17 
 
PA is also characterized by cardiovascular and renal damage (Rossi et Al. 1996), 
which is often more marked than that found in patients with essential hypertension 
and similar blood pressure values (Savard et al. 2013).  Since correction of PA 
may prevent or reverse target organ damage, diagnosis of PA is of utmost 
relevance for preventing target organ damage.  
 
 
Diagnosis of PA 
 
Hiramatsu et al. introduced the aldosterone-to-renin ratio (ARR) as a 
screening test to identify PA in 1981. After then, ARR remains the cornerstone for 
diagnosing PA, as confirmed by the 2008 Guidelines of the International 
Endocrine Society. Two simultaneous blood tests are required to calculate ARR: 
the plasma (or serum) aldosterone concentration (PAC) and the plasma renin 
activity (PRA). 
ARR = PAC/PRA 
 
The ARR is a crude bivariate analysis; hence, its value depends on plasma 
aldosterone concentration (PAC) and on levels of renin. However, very different 
PAC and renin values can produce the same ratio. Moreover, the assays that are 
currently available for measuring plasma renin activity (PRA) and direct renin 
assay (DRA) lose their precision when levels of renin are low. As a result of this 
loss of sensitivity, and to avoid overinflating the ARR when levels of renin are 
very low, the lowest renin value that can be included in the ratio is often fixed at a 
minimum (which is 0.2 ng/ml per h for PRA).  
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Thus, rather than using the ARR purely arithmetically, the combination of an 
increased ARR and a PAC >416 pmol/l (15 ng/dl) should be used to detect 
patients with PA and regarded as indicative of this condition.Widely different cut-
off values of ARR have been proposed for PA diagnosis. However, in the largest 
study published to date, which examined 126 consecutive hypertensive patients 
referred to 14 specialized centers for hypertension in Italy, by using the diagnosis 
of APA as the gold standard for identifying PA patients and the receiver operating 
characteristic (ROC) curves and the Youden index for the analysis, the ARR 
optimal cut-off was 26 (Rossi 2006). This value corresponded to a sensitivity of 
80.5% and a specificity of 84.5%.  
By definition a screening test must be highly sensitive to avoid that any patient(s) 
with PA is undetected. This requirement implies that the test often gives false-
positive results that need to be identified before addressing the patients to the 
adrenal-vein sampling. This latter, as reported in detail below, may be risky. The 
oral sodium loading test, the saline infusion test, the captopril challenge test and 
the fludrocortisone with salt-loading test, are the tests currently used to exclude 
false positive results. The purpose of these tests is to demonstrate that the excess 
secretion of aldosterone is autonomous from the renin–angiotensin system. 
Unfortunately, these tests cannot provide unequivocal information because 
aldosterone secretion is dependent on angiotensin not only in patients with 
idiopathic hyperaldosteronism, but also in many patients with APA. Hence, if the 
ARR is properly determined, a notably raised value is a strong indication that the 
patient has PA.  
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Subtype of  PA 
The most common forms of PA are aldosterone-producing adenoma (APA) 
and bilateral adrenocortical hyperplasia (BAH), also referred to as idiopathic 
hyperaldosteronism (IHA). PA can be classified as surgically and not surgically 
curable: 
 
1. Surgically curable: 
 
v Aldosterone-producing adenoma (aldosteronoma, APA) 
v Multinodular unilateral adrenocortical hyperplasia (MUAN) 
v Phaeochromocytoma causing Primary aldosteronism 
 
 
       2. Surgically not curable: 
 
v Bilateral adrenal hyperplasia (BAH) 
v Unilateral APA with BAH 
v Familial hyperaldosteronism  
 
 
The patients positive at the screening test should undergo imaging tests for 
identification of adrenocortical nodules and AVS to distinguish between unilateral 
and bilateral excess production of aldosterone (Rossi GP, et Al. 2006) (Rossi et 
Al. 2001). A high resolution CT scan with 2–3 mm cuts represents the best 
available technique for identifying adrenal nodules, which can be APA, primary 
unilateral adrenal hyperplasia or bilateral adrenal hyperplasia. Imaging is crucial 
to identify the rare but large aldosterone-producing carcinoma. 
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Half of APAs are <20 mm in diameter and up to 42% are <6 mm in diameter, 
therefore, most patients with primary aldosteronism attributable to an APA who 
can be cured with surgery have a small or very small tumour. Other surgically 
curable subtypes of primary aldosteronism, such as primary aldosteronism caused 
by primary unilateral adrenal hyperplasia or multinodular unilateral adrenocortical 
hyperplasia, have nodular lesions that are also most often very small (<10 mm in 
diameter), which makes them hardly detectable with CT or MRI. Hence, an 
imaging-guided strategy for subtype differentiation of PA would result in missing 
masses producing excess aldosterone and in revealing adrenal masses that are not 
APAs. Moreover, imaging is inadequate to achieve discrimination between APA 
and idiopathic hyperaldosteronism. 
 
 
Adrenal Vein Sampling (AVS) 
 
 
Patients with PA could have either bilateral (BAH) or unilateral (APA) adrenal 
disease (Chao CT et Al. 2013). Since unilateral and bilateral forms require 
different treatments, it is of crucial relevance to discriminate between them. In 
fact, unilateral forms can be treated by laparoscopic adrenalectomy, whereas 
bilateral forms need medical management with mineralocorticoid receptor 
antagonists.  Of interest, surgery can normalize serum K+ concentrations in almost 
all PA cases, and cure or improve hypertension in more than 80% of cases with 
unilateral forms (Letavernier E et Al. 2008).  
The Endocrine Society Guidelines claim adrenal vein sampling (AVS) as the gold 
standard to distinguish between unilateral from bilateral aldosterone 
hypersecretion (Funder JW et Al. 2008, Rossi GP et Al. 2014). However, since 
AVS procedure is technically demanding, and carries a tiny, but not negligible, 
risk of adrenal-vein rupture (Daunt N et Al. 2005, Rossi 2011) it is recommended 
only in PA patients who are eligible for surgical management. 
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AVS includes measurement of both aldosterone and cortisol in the inferior vena 
cava and adrenal veins. The measurement of cortisol, besides that of aldosterone, 
is essential for calculation of the selectivity index that confirms catheter 
placement and corrects for dilution during sampling (Figure 7).  
Measurements of both steroids are also crucial for calculating the lateralization 
index, corresponding to PAC: PCC ratio on the dominant side over the PAC: PCC 
ratio on the contralateral side of the adrenal gland. Lateralization index provides 
an accurate diagnosis of PA with lateralized excess aldosterone production. 
 
 
 
	  
Figure	  7:	  Placement	  of	  the	  catheter	  in	  the	  adrenal	  veins	  
(From	  website	  of	  Department	  of	  Radiology,	  Massachussets	  General	  Hospital)	  
	  
	  
 
Some investigators also propose the use of the contralateral suppression index, 
defined by the aldosterone/cortisol concentration ratio of the non-dominant 
adrenal vein divided by the peripheral aldosterone/cortisol concentration ratio. 
(Rossi GP, et al. 2012). However, there are no evidence that suppression index 
provides more accuracy than lateralization index alone.  
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The performance of AVS and the interpretation of its results are generally 
regarded as challenging, (Stewart PM et Al. 2010) mainly due to the lack of 
accepted criteria to define selectivity of adrenal vein catheterization and 
lateralization of aldosterone excess (Rosenquist KJ, Dluhy RG. 2011). For these 
reasons and the recognized lack of reliability of alternative methods such as CT 
and biochemical tests for distinguishing unilateral from bilateral disease (Funder 
et Al. 2008) many patients with PA still undergoing adrenalectomy without prior 
demonstration of lateralized aldosterone excess. This practice can lead to 
unnecessary adrenalectomy and/or removal of the wrong adrenal in a substantial 
proportion of cases, as recently shown (Young WF, et Al. 2004, Kempers MJ, et 
AL 2009). Hence, development of new methods alternative to AVS could be very 
useful to support a certain diagnosis of PA 
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Diagnosis of Aldosterone Producing Adenoma (APA)  
 
Identification of APA requires each of the following four corner criteria (Rossi et 
al Hypertension 2010):  
 
• Evidence of PA at the screening test as defined above; 
• Lateralization of aldosterone secretion at AVS  
• Evidence of adenoma at pathology; 
• Demonstration of normokalemia and cure or improvement of hypertension 
at follow-up after adrenalectomy. 
 
Hence, after demonstration of lateralized excess aldosterone production, 
diagnosis of APA also requires evidence of a nodule at histology with ZG-or 
ZF-like cells, and correction of hypokalemia and cure or improvement of 
hypertension at follow-up after surgery. Histology and follow-up are therefore 
crucial issues for reaching a conclusive diagnosis of APA, which represents 
the only subtype of PA that can receive unequivocal diagnosis.  Patients with 
biochemical evidence for PA but without conclusive evidence for lateralized 
aldosterone excess are presumed to have IHA.  
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Genetic alteration in the development of   
Aldosterone Producing adenoma (APA) 
 
 
Somatic mutations in KCNJ5 gene in APA 
 
 
 
The KCNJ5 gene, which is located on 11q24.3 chromosome, codes for 
Kir3.4, a member of the G-protein-activated inwardly rectifying potassium 
channel family (subfamily J, member 5). Kir3.4 is expressed in the ZG, where it 
forms a highly active heterotetramer with Kir3.1 (KCNJ3) that contributes to 
maintenance of the K+ equilibrium potential across the cell membrane. It also can 
form a homotetramer, which is less active than heterotetramer. Under physiologic 
conditions, both Kir3.4 and Kir3.1 draw K+ out of the cell thereby maintaining 
hyperpolarization of ZG membrane at rest. Selective transit of K+ through the 
channel pore is conferred by a GYG motif located at the narrowest part of the 
pore. This selectivity filter is very well conserved among different species and 
among the other channel in the family, supporting the concept of its crucial role. 
A loss-of-function mutation in KCNJ5 was found to cause a rare form of long QT 
syndrome. (Yang Y, Yang Y, Liang B, et al. 2010).  More recently, by using 
whole-genome sequencing to search for somatic mutations, Choi et al. found 2 
recurrent mutations in 8 cases (38%) of a cohort of 22 APA patients. These 
mutations, corresponding to p.Gly151Arg (G151R) or p.Leu168Arg (L168R), 
occurred within or near the selectivity filter and altered the channel’s selectivity. 
G151 constitutes the first glycine in the GYG motif, whereas L168’s side chain 
abuts the side chain of the tyrosine in the same motif (Y152). KCNJ5 channels 
that contain these mutations conduct Na+, with chronic depolarization, constitutive 
aldosterone production, and cell proliferation.   
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A novel mutation has been recently detected in our laboratory (Kuppusamy, et al, 
J Clin Endocrinol Metab 2014), characterized by threonine insertion before the 
selectivity filter of the K+ channel. Such mutation causes loss of K+ selectivity, 
Na+ permeability and Ca2+ influx via opening of voltage calcium channels and 
impairment of Na+/Ca2+ exchangers, leading to enhanced CYP11B2 expression 
and a constitutive over-secretion of aldosterone from the tumor (Figure 8). 
 
 
	  
	  
Figure	  8:	  Activity	  of	  KIR	  3.4	  channel	  	  
	  
 
 
Functional studies have confirmed that mutated KCNJ5 can promote aldosterone 
synthesis: CYP11B2 messenger RNA (mRNA) levels were found to be 
upregulated in APAs with KCNJ5 mutations by a factor of 3.1 (compared to cells 
isolated from APAs without KCNJ5 mutations) (Monticone S, et al. 2012). 
However, the mechanisms by which chronic Ca2+ stimulation activates 
aldosterone production in ZG cells remain unclear.  
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Visinin-like 1 (VSNL1, a neuronal calcium-sensor protein that participates to the 
transduction of calcium signaling) was found to be over-expressed in APAs 
harboring KCNJ5 mutations. Increased expression of VSNL1 was suggested to 
protect the cells from calcium overload caused by the mutation. In fact, calcium 
overload can be dangerous for cell survival by promoting signaling pathways 
leading to death. (Williams TA, et Al. 2012).  
Mulatero et al. also found a somatic p.Thr158Ala (T158A) mutation in an Italian 
patient with APA and a family history of PA. The same mutation had been 
reported in the original article by Choi et al but as a germline mutation. Threonine 
in position 158 is a well-conserved amino acid that forms hydrogen bonds with 
two conserved residues (P128 and C129) in the loop between the first 
transmembrane domain and the pore helix, and thus constrains the structure. The 
T158A mutation eliminates these hydrogen bonds thereby modifying channel 
selectivity. To date, only four other somatic mutations in KCNJ5 have been 
reported in APA patients. Each mutation has been reported only once: a deletion 
mutation affecting isoleucine 157 (p.Ile157del), which is presumed to induce a 
conformational change near the selectivity filter; (Azizan EA et Al. 2012) two 
substitutions, which both affect the same amino acid (glutamic acid 145), 
p.Glu145Gln (E145Q) and p.Glu145Lys (E145K)(Azizan  et Al. 2013), and a 
p.Trp126Arg (W126R) mutation. (Williams TA, Monticone S et Al. 2014).  
Either (G151R) or (L168R) is present in 99% of KCNJ5-mutated APAs, whereas 
the five other mutations are extremely rare. KCNJ5 somatic mutations are present 
in approximately 40% (range: 13%–65%) of APAs, thereby showing that they are 
more frequent than supposed some years ago (Boulkroun S, Beuschlein F, Rossi 
GP, et Al. 2012). However, the proportion of APAs with KCNJ5 mutations differs 
considerably from one center to another, reflecting disparities in the criteria used 
to differentiate unilateral from bilateral PA and to establish the diagnosis of APA.  
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The highest prevalence (65.2%) was found in a Japanese study. Of interest, 
studies from Japan report much higher prevalence of mutated APAs than that 
found in Western countries. (Taguchi R et Al. 2012).  
Moreover, gender differences were also noticed: KCNJ5 mutations are more 
frequent in women than in men. Nevertheless, the prevalence of KCNJ5 mutations 
was higher in Japanese men than in women, thereby suggesting epidemiological 
marked differences between Japanese and Western populations.  
 
 
 
Somatic mutations in ATP1A1 
 
 
The ATP1A1 gene encodes the alpha-1 (catalytic) subunit of the Na+/K+ 
ATPase, a member of the P-type ATPase family. It maps to chromosome 1p13.1 
and comprises 10 transmembrane segments (from M1 to M10). There are two 
functionally important cytoplasmic loops: a large loop between M4 and M5 
(which binds ATP) and a small loop between M2 and M3 (which has a key role in 
energy transduction). Upon activation, the transmembrane segment M1 interacts 
and cooperates with segment M4 to facilitate ion binding. For each ATP 
hydrolyzed, the Na+/K+ ATPase transports two K+ ions into the cell and three Na+ 
ions out of the cell. The resulting potassium and sodium gradients contribute to 
the resting membrane potential and action potentials. ATP1A1 is strongly 
expressed in the ZG and to a lesser degree in the ZF. Recently, Beuschlein et al. 
performed exome sequencing of tumor and matched control tissue samples from 
nine males affected with hypokalemic PA and bearing wild-type Kir3.4.  They 
found that three patients had somatic ATP1A1 mutations: substitution of the 
leucine in position 104 (in M1) p.Leu104Arg (L104R) in two cases and sub-
stitution of the valine in the position 332 (in segment M4) p.Val332Gly (V332G) 
in the third case. Both amino acids are highly conserved among species and 
among different members of the P-type ATPase family.  
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Beuschlein et al then sequenced the entire coding region of ATP1A1 in an 
additional 100 APAs and detected six cases with somatic mutations: four had the 
L104R mutation, while the other two featured a five amino acid deletion 
(p.Phe100_Leu104del). Targeted sequencing of the affected genomic locations 
was performed in 199 additional APAs and confirmed that ATP1A1 mutations are 
present in 5.2% of patients with APA. (Beuschlein F et al. 2013). The sequencing 
data indicated that both wild type and mutated alleles were present in tumor 
tissues suggesting that the mutation was heterozygous. All mentioned alterations 
in the ATP1A1 gene disrupt the glutamic acid in position 334 (site II), which is 
crucial for sodium and potassium ion binding and gating of the binding pocket. 
Beuschlein et al. also examined the functional impact of the ATP1A1 mutations 
and found that mutated ATP1A1 have impaired activity. Adenoma cells with an 
ATP1A1 mutation showed substantially higher levels of depolarization. Hence, the 
mutations in ATP1A1 change the transport mode from active pumping (three Na+ 
outwards and two K+ inwards) to passive conduction (inward current due to 
protons or Na+ ions, depending on the mutation) (Figure 9). This impairment in 
conduction leads to membrane depolarization, opening of voltage-gated calcium 
channels, increased intracellular calcium and thus increased CYP11B2 expression 
with aldosterone hyper-production.  
A new somatic mutation (p.Gly99Arg, G99R) has been recently reported. Glycine 
99 interacts with isoleucine 292 to mediate the opening of the gate at the entrance 
of the binding pocket, while Arginine in the position 99 alters the surrounding 
structure (Williams TA et Al. 2014). 	  	  	  	  	  	  
	  
	  
	  
 29 
	  
	  
	  
Figure	   9:	   The	   molecular	   mechanisms	   underlying	   hyperaldosteronism	   in	   patients	   with	   ATP1A1	  
mutations.	  The	  Na+/K+	  ATPase	  changes	  from	  actively	  pumping	  (3	  Na+	  outwards	  and	  2	  K+	  inwards)	  
to	   passive	   conduction	   of	   an	   inward	   current	   (protons	   or	   Na+	   ions,	   depending	   on	   the	  
mutation)(From	  website	  The	  applications	  of	  Clinical	  Genetics	  2014)	  
	  
 
	  
Figure	  10:	  A	  schematic	  diagram	  of	  the	  structure	  of	  Na+/K+	  ATPase	  subunit	  alpha	  1	  (upper	  panel,	  
ATP1A1),	  Ca2+	  ATPase	  3	   (middle	  panel,	  ATP2B3)	  and	   the	  alpha	  subunit	  of	   low-­‐voltage	  activated	  
calcium	   channel	   Cav1.3,	   with	   known	  mutations	   indicated	   by	   red	   circles	   (lower	   panel).	   (Nature	  
Genetics,	  Beuschlein	  F,	  Boulkroun	  S,	  Osswald	  A,	  et	  al.	  2013)	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Somatic mutations in ATP2B3 	  
 
 
The ATP2B3 gene encodes the plasma membrane calcium transport 
ATPase 3 (PMAC3), another member of the P-type ATPase family. Its structure is 
similar to that of ATP1A1, with 10 transmembrane segments and two functionally 
important cytoplasmic loops (Figure 9). ATP2B3 is required for clearing calcium 
from the cytoplasm of eukaryotic cells and thereby has an important role in 
intracellular Ca2+ homeostasis. ATP2B3 is located on the X chromosome (Xq28) 
and is expressed throughout the adrenal cortex. Beuschlein et al. reported three 
different in-frame deletions that resulted in either p. Leu425_Val426del or p. 
Val426_Val427del. These deletions affect a highly conserved residue and thus 
alter the M4 transmembrane helix in a region that is thought to be crucial for 
calcium ion binding. A functional study confirmed that ATP2B3 mutations impair 
activity and inactivate pump function: cultured adenoma cells with an ATP2B3 
mutation showed substantially higher levels of depolarization. Another mutation 
consisting in a deletion (c.1281_1286delGGCTGT) had been recently reported.  
Several studies have shown that ATP2B3 mutations have lower prevalence than 
KCNJ5 in APA patients (0.9%–1.6%), and also that they are associated with 
severe forms of PA and are more common in men than in women. APAs with 
ATPase mutations were found to be smaller than APAs with KCNJ5 mutations. 
Of interest, KCNJ5 mutations were never found associated with ATP1A1 or 
ATP2B3 mutations in the same tumor.  
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Somatic mutations in CACNA1D 
 
The CACNA1D gene encodes Cav1.3, the alpha subunit of an L-type 
voltage-gated calcium channel. This family of channels is characterized by 
sensitivity to dihydropyridine calcium channel blockers, which act as weak 
antagonists of Cav1.3. High-voltage-gated calcium channels differ from low-
voltage-gated calcium channels (T-type channels) in terms of the voltage 
dependence of opening and inactivation and the kinetics of closure and 
inactivation. Cav1.3 is composed of four homologous repeats (I–IV), each of 
which has six transmembrane segments (S1–S6) and a membrane-associated loop 
between S5 and S6 (Figure 10). The channel’s pore is formed by the S5, S6 and 
the loop. The CACNA1D gene is located on 3p14.3. Alternative splicing gives rise 
to many different isoforms. CACNA1D is expressed in the ZG and in many other 
tissues (heart, neurons, cochlear hair cells). By performing exome sequencing, 
Scholl et al. found two somatic mutations in CACNA1D in 18 cases of APA. Both 
mutations affected well-conserved amino acids (p. Gly403Arg and p. Ile770Met) 
located at the cytoplasm ends of the S6 segment of repeats I and II. When 
expressed in HEK293T cells, both mutant genes were found to be associated with 
peak current amplitudes at less depolarized potentials, suggesting that mutations 
lead to channel opening at lower potentials. Scholl et al. sequenced all S6 
segments in an additional 46 APAs, and they identified three additional somatic 
mutations. Easier activation of the mutant channels resulted in increased Ca2+ 
entry and greater aldosterone production. These mutations more frequently occur 
in males than in women, and are also more frequent in small than large APAs. 
Whether the smaller dimension of the APA is related to the abundance of ZG-type 
cells, which are lipid-poor and smaller than lipid-rich ZF-type cells, remains to be 
confirmed (Brown MJ et Al. 2014). 
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Familial hyperaldosteronism type 1 (FH-1) 
 
In 1966, Sutherland el al. described the case of a father and son with hypertension 
due to hyperaldosteronism that was relieved by dexamethasone treatment. 
Familial hyperaldosteronism type I (called as FH-I according to the new 
nomenclature,   Lenzini L et Rossi GP 2015) is also known as glucocorticoid-
remediable aldosteronism (GRA) and is characterized by severe, early-onset 
hypertension. Although GRA accounts for less than 1% of patients with PA, it is 
considered to be the most common form of monogenic hypertension. Patients with 
GRA have an elevated risk of early haemorrhagic stroke and secrete high levels of 
hybrid steroids (18-hydroxycortisol and 18-oxocortisol). Glucocorticoid-
remediable aldosteronism is inherited as an autosomal, dominant trait. The 
molecular etiology of GRA was characterized in 1992 and is based on unequal 
crossing-over between the 11 β-hydroxylase (CYP11B1) and aldosterone synthase 
(CYP11B2) genes, which results in a chimeric gene that combines the 5′ promoter 
region of the 11 β-hydroxylase with the coding region of aldosterone synthase 
(Figure 11). The final effect is that aldosterone synthesis is regulated by ACTH 
(rather than by the renin-angiotensin system) and has a circadian rhythm similar to 
that of cortisol. This aberrant regulation explains why dexamethasone 
administration reduces aldosterone levels and normalizes blood pressure levels. 
GRA can be easily diagnosed with a polymerase chain reaction-based assay and, 
therefore, dexamethasone suppression test and hybrid steroid assays are no longer 
required. The Endocrine Society recommends genetic testing in patients with 
confirmed PA before the age of 20 and in those who have a family history of PA 
or strokes at a young age. 
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Figure	  11:	  The	  molecular	  mechanism	  underlying	  GRA.	  Unequal	  crossing-­‐over	  between	  the	  11	  β-­‐
hydroxylase	  (CYP11B1)	  and	  aldosterone	  synthase	  (CYP11B2)	  genes	  results	  in	  a	  chimeric	  gene	  and	  
the	  control	  of	  aldosterone	  secretion	  by	  ACTH.	  (From	  The	  Application	  of	  Clinical	  Genetics,	  2014)	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Familial hyperaldosteronism type 2 (FH-2)  
 
In 1992, Stowasser et al (Stowasser M et Al. 1992) described a second 
form of hereditary hyperaldosteronism in 13 patients with PA from 5 families. 
Because this form of PA did not respond to glucocorticoid treatment, genetic test 
for FH-1 was performed. The test showed lack of the chimeric gene, leading to 
identification of a novel syndrome that was classified as familial hyperal- 
dosteronism type 2 (FH-2) (OMIM: 605635) only because of the familial 
occurrence (Lenzini L et Rossi GP 2015). FH-2, which comprises both 
adrenocortical hyperplasia and/or APA, is clinically undistinguishable from 
sporadic primary aldosteronism. The true prevalence of this form is not known, 
but is supposed to be as high as 6% in patients with PA. FH-2 is transmitted in an 
autosomal dominant fashion and although linkage analysis identified a 
quantitative trait locus (QTL) on chromosome 7p22 the responsible gene(s) 
remain unknown.  
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Familial hyperaldosteronism type 3 (FH-3) 
 
 
In 2008 a third form of familial hyperaldosteronism was described. 
Hypertension was refractory to combination therapy in all three members of a 
family for which genetic test ruled out GRA as the cause of the clinical picture. 
Members of this family developed severe hypertension in childhood (before the 
age of 7), severe hypokalemia, and PA with very high levels of hybrid steroids 
(18-oxocortisol and 18-hydroxycortisol). The excised adrenals revealed a thin, 
atrophic ZG, a slightly decreased zona reticularis, and diffuse hyperplasia of the 
ZF (Geller DS et Al. 2008). The genetic basis of this syndrome was discovered 
three years later, when a germline heterozygous T158A mutation in KCNJ5 was 
found in all affected members. Oki et al. demonstrated that expression of the 
T158A mutant in HAC15 cells caused increased Na+ inflow, higher plasma 
membrane voltage, increased intracellular calcium levels with enhanced aldos-
terone production. Cell proliferation was lower in the T158A mutant than in the 
wild type. Scholl et al. reported four additional families with FH-3 and a 
surprising genotype-phenotype correlation: two of the four families had a clinical 
course similar to that of the patients with the T158A mutation. Upon genetic test-
ing, both families were found to have a germline mutation identical to one of the 
recurrent somatic KCNJ5 mutations found in APAs (G151R). Of interest, the 
other two families had a germline mutation that affected the same amino acid but 
resulted in a glycine to glutamic acid substitution (G151E). This G151E mutation 
was more severe and associated with poorer survival than the other mutations. 
Scholl et al. suggested that the increase in Na+ conductance is responsible for cell 
death, which hinders the formation of adenoma and/or hyperplasia (Scholl UI et 
Al. 2012).  
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Germline mutations in CACNA1D cause primary aldosteronism 
 
After discovering CACNA1D somatic mutations in APAs, Scholl et al. 
searched for CACNA1D germline mutations in PA patients. They screened 100 
unrelated patients with early onset PA and found two de novo mutations, which 
affected amino acids known to be target of somatic mutations in APA. The first 
subject had suffered from hypertension and heart disease since birth. 
Hypertension was refractory to treatment until amlodipine was used. The subject 
also exhibited seizures, cortical blindness, and neuromuscular abnormalities. He 
was found to harbour a p.Gly403Asp mutation in CACNA1D. The second subject 
had cerebral palsy, spastic quadriplegia, mild athetosis, severe intellectual 
disability and seizures. By the age of 5 years, he displayed hypertension and 
hypokalemia. Genetic testing revealed a p.Ile770Met mutation in CACNA1D. 
Because only two cases have been reported to date, definition of a phenotype for 
this association between germline CACNA1D mutations and PA could be 
premature. Whether the clinical picture invariably affects many systems remains 
unclear. 
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Circulating-DNA:  
A promising biomarker for early diagnosis of  APA? 
 
 
 
 
Circulating cell-free DNA  
 
 
Cell-free fragments of DNA (cf-DNA) are extracellular nucleic acids that 
circulate freely into the bloodstream. Elevated levels of cf-DNA were first 
reported by Leon et al. in 1977 in the blood of patients with cancer. Since then, 
several studies confirmed the initial observation by Leon et al. (reviewed in 
Gormally et al), mostly in patients with breast and lung cancer (Chen XQ et Al 
Nature Medicine 1996, Sánchez-Céspedes M et al 1998). Although the discovery 
of cf-DNA occurred more than seventy years ago, the source of cf-DNA remains 
still unclear and enigmatic. Several hypotheses were developed to explain the 
mechanisms of DNA release, but release from necrotic or apoptotic cells are the 
most accredited concept. 
Cf-DNA can be considered as a photocopy of the cell that release it into 
the bloodstream. Therefore, it can give important information on genetic 
alterations, allelic imbalance and even presence of viral gene. For all these 
reasons, the fields of interest of cf-DNA as a predictive, diagnostic and non-
invasive tool may be very numerous not restricted to oncology (Figure 12). 
Whether cf-DNA may allow detection of mutations is an emerging field of 
research.  
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Figure	  12:	  	  Potential	  applications	  of	  cf-­‐DNA	  	  	  
	  	  	  	  	  	  	  	  	  	  (From	  Transl	  Med,	  2014)	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Origin of circulating-DNA: Cell Apoptosis and Necrosis  
 
 
 
 Apoptosis and necrosis are two distinct mechanisms of cell death and 
represent two extremes of the same phenomenon (DKanduc et Al. 2002). cf-DNA 
can be released from apoptotic or necrotic cells, reflecting a differential DNA 
origin, as well as from living cells through an active release (Van der Vaart M et 
Al. 2008, Chen Z et Al. 2005).  
Tumor necrosis is a frequent event in solid malignant neoplasms, and it generates 
a spectrum of DNA fragments with different strand lengths because of random 
and incomplete digestion of genomic DNA by a variety of deoxyribonucleases. In 
general the length of these fragments of DNA is approximately 400–500 bp. 
However, in patients with cancer cf-DNA is released not only from necrotic cells, 
but also from cells undergoing apoptosis, autophagy, or mitotic catastrophe (Jin Z 
et Al. 2005). 
Cell death in normal tissues occurs mostly via apoptosis that generates small and 
uniform DNA fragments usually from 185 to 200 bp in length (Giacona MB et.Al 
1998; Chan KC et Al 2008); this uniformly truncated DNA is produced by a 
programmed enzymatic cleavage process (Wyllie AH et Al. 1980).  
Hence, cf-DNA is mainly released from apoptotic cells in healthy subjects 
whereas from necrotic cells in patients with cancer and, therefore, elevated levels 
of long DNA fragments could be used as marker of malignant tumor in blood.  
Recent studies showing increased levels of long cf-DNA in plasma from patients 
with breast (Umetani N et Al. 2006) and gynecologic cancers (Wang BG et Al. 
2003) compared to the levels of healthy subjects, support this contention. (Sabine 
Jahret et Al. 2001). 
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  Figure	  13:	  	  Different	  Mechanisms	  of	  release	  of	  cell-­‐	  free	  DNA	  in	  bloodstream	  	  
(Nature	  2013)	  
	  
 
 
Since the length of cf-DNA reflects the mechanisms, apoptosis or necrosis, by 
which DNA fragments are generated (Figure 13), the ratio of longer-to-shorter 
fragment concentration, also known as fragmentation index (DII), can be assumed 
as measurement of DNA integrity. 
 
	  
 
 
 
 
 41 
 
 
 Aims 
 
 
The general aim of our study was to test the hypothesis that DNA released into 
bloodstream from the APA cells that harbour a KCNJ5 mutation (mutated) also 
contains the KCNJ5 mutation. Because the contralateral adrenal gland (wild type) 
contains no mutation, detection of KCNJ5 mutation in the adrenal venous blood 
would be much easier from the APA side. 
 
 
Specific aims: 
 
1. To develop an accurate but less time consuming method than Sanger 
sequencing to pinpoint KCNJ5 mutations in the APA tissue.  
 
 
2. To isolate cf-DNA from the adrenal veins and inferior vena cava in the 
patients undergoing AVS.  
 
 
3. To evaluate if this method could be also used tno identify KCNJ5 
mutations in cf-DNA isolated from the adrenal vein blood draining the 
APA with know KCNJ5 mutations. 
 
4. To investigate the fragmentation level of cf-DNA. Different levels of 
fragmentation maybe suggestive of apoptosis or necrosis and, therefore, 
fragmentation could provide information on the mechanisms by cf-DNA is 
released from APA cells.  
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Flow-chart of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
 
 
 
 
 
 
 
KCNJ5	  mutations	  were	  found	  in	  40%	  of	  the	  APAs	  but	  not	  in	  BAH	   
KCNJ5	  mutations	  are	  involved	  in	  germline	  heterozygous	  mutations	  (FH-­‐3) 
Can	  KCNJ5	  mutations	  in	  peripheral	  blood	  be	  considered	  a	  
biomarker	  of	  APA? 
Can	  KCNJ5	  mutations	  be	  detected	  in	  cf-­‐DNA	  released	  into	  the	  
bloodstream	  from	  APA	  KCNJ5	  mutated	  cells? 
Gold	  standard	  technique 
(DNA	  Sanger	  sequencing) 
Strategy	  developed 
in	  our	  laboratory 
Comparison	  between	  strategies 
50	  patients	  undergoing	  adrenalectomy 
because	  of	  unilateral	  excess	  aldosterone	  production 
Isolation	  of	  cf-­‐DNA	  from	  venous	  adrenal	  and	  vena	  cava	  
blood	  of	  one	  patient	  with	  KCNJ5	  mutation	  in	  the	  APA	   
Background 
Question	  1	    
Identification	  of	  30	  mutated	  pts 
No	  misclassification 
Measurement	  of	  fragmentation	  index 
Identification	  of	  the	  KCNJ5	  mutation	  in	   
Cf-­‐DNA	  isolated	  from	  adrenal	  vein	  blood	  
draining	  blood	  from	  the	  APA	  side 
	   	   	  	   	   	   STEP-­‐-­‐ 1 
	   	  	   	   STEP-­‐-­‐ 2 
Question	  2	    
Identification	  of	  30	  mutated	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Materials and Methods 
 
 
 
 
 
DNA Extraction from APA tissue 
 
 
The adrenal gland tissue was obtained from PA patients with lateralized 
excess production of aldosterone undergoing adrenalectomy. The tissue was 
collected under sterile conditions in the operating room after cutting the gland into 
halves. Half of the adrenal was sent to the pathology department for histology and 
the remaining tissue was used for downstream analysis. The diagnosis of APA 
was confirmed at histopathology and moreover, all patients displayed 
normokalemia and improvement in blood pressure control at postoperative 
follow-up. Hence, all four corner criteria were satisfied in each patient. 
 DNA was isolated from 40 mg of tissue previously cut in small pieces (about 3-4 
mm3) using Euro Gold Tissue-DNA Mini Kit according to manufacture 
instructions. Elution final volume was 100 ul. Evaluation of the concentration and 
purity of DNA as a ratio of absorbance at 260 nm and 280A (ratio of ~1.8 is 
generally accepted as “pure” for DNA) was assessed with Thermo Scientific Nano 
Drop 2000 spectrophotometer.  
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Taq-Man probe  
 
 
Three different couples of primers for KCNJ5 gene were drawn to evaluate 
the presence of mutation in the DNA extracted from tissue of APA patients. In 
particular, two couples of primers recognized the most frequent mutated regions   
that include G151R and L168. Both primers produced 200 bp amplicons. The 
third couple of primers generated a 400 bp product of PCR that covers both 
mutations (G151R and L168R).  
Five different Taq-man hydrolysis probes were designed to increase the 
specificity of quantitative PCR thanks to the perfect binding of oligonucleotides 
that recognize both wild type and mutated regions. A Taq-man probe consists of 
two types of fluorophores, which are the fluorescent parts of reporter proteins. 
While the probe is attached to the DNA template and before the polymerase acts, 
the quencher (Q) fluorophore reduces the fluorescence of the reporter (R) 
fluorophore. 
 
 
	  
	  
Figure	  14:	  Scheme	  of	  a	  Taq-­‐Man	  probe	  
	  
 
During the PCR reaction, exonuclease activity of Taq- polymerase cleaves a dual-
labeled probe during hybridization to the complementary target sequence and this 
allows the separation of the quencher from the reporter that is able to issue the 
fluorescence.  
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Hence, fluorescence detected in the quantitative PCR thermal cycler is directly 
proportional to the fluorophore released and also to the amount of DNA template 
generated during PCR reaction.  
 
 
	  
	  
Figure	  15:	  Release	  of	  reporter	  by	  Polymerase	  and	  emission	  of	  fluorescence	  during	  Q-­‐PCR	  
	  
 
We used the following fluorophores for TAQ-MAN probes: 
 
1. 5’FAM, 3’BHQ1 for wild type region of G151R 
2. 5’Texas Red, 5’HEX 3’BHQ1 for mutated regions of G151R 
 
3. 5’FAM, 3’BHQ1 for wild type region of L168R 
4. 5’Texas Red, 5’HEX 3’BHQ1 for mutated region of L168R 
 
	  
	  
Figure	  16:	  Design	  of	  Taq-­‐man	  Probe	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Gradient curve  
 
Before performing Q-PCR, a gradient curve was done to verify the best 
annealing temperature (Ta) of the primers. Melting curves were obtained by 
increasing the temperature from 65°C to 95°C with a plate that was read every 
0.3°C after holding the temperature for 5 sec. For G151R and L168R the gradient 
curve was performed from 65°C to 55°C. 
 
 
Real time PCR (Q-PCR)  
 
 
CFX96 Touch Real-Time PCR machine (Bio-Rad) was used to perform 
the reactions of Real Time PCR (Q-PCR) for KCNJ5 gene. Q-PCR amplifications 
were carried out in a reaction final volume of 25 ul. Each PCR reaction mixture 
was composed of 12.5 ul of PCR mix (SsoFast™ Eva Green® Super mix Bio-
Rad) 1.5 ul of each primer (300nm/ul) 4.5 ul of water and 5 ul of DNA extract. 
Every reaction was carried in duplicate. Thermal cycling was organized in 3 
repeated steps: a first denaturation step of 3 min at 95°C, followed by 40 repeated 
cycles of 95°C for 10 sec and 60°C for 30 sec. Q-PCR amplifications with Taq 
Man Probe were carried out in a reaction final volume of 15 ul.  Each PCR 
reaction mixture was composed of 10.8 ul of PCR mix (Sso Advanced universal 
Probes supermix Bio-Rad, Berkeley California) 1.2 ul of each primer (300nm/ul) 
and 0.45 ul of probes (300nm/ul). 
Thermal cycling conditions included the following 3 steps: denaturation of 3 min 
at 95°C, followed by 40 repeated cycles of 95°C for 10 sec, and finally 55°C for 
30 sec. To verify the presence of the mutation the three probes were loaded in 
same well of PCR plates. Two amplification curves were obtained, one 
corresponding to the wild type and the other one to the mutated region.   
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Allelic discrimination by Genotype Assignments 
 
 
Assignment of genotypes to wild type or mutant, i.e. allelic discrimination, 
was based on the analysis of the amplification plots generated for each allele-
specific TAQ-MAN probe (FAM, Texas Red, and HEX). Allelic discrimination 
analysis was performed using a module included in the software package of 
CFX96 I Cycler IQ Touch Real-Time PCR machine (Bio-Rad Hercules, United 
States). 
After assigning genotypes, the software packages analyze either the final relative 
fluorescent units (RFU) or the Ct values and reported graphs data as scatter plot. 
In this way, the genotypes assigned to each gene were plotted, thereby allowing 
discrimination between alleles. 
 
 
Sanger Sequencing  
 
Sanger sequencing was performed to confirm the results obtained with Q-
PCR using the Taq Man probes. The PCR product was purified with QIAquick 
PCR Purification Kit according to manufacture instructions (Qiagen, Hilden, 
Germany) and eluted to 40 ul final volume. The PCR purified product (25 ul + 5 
ul of Gel Loading Buffer with DNA Stain (Jena Bioscience) was loaded on 2% 
Agarose gel  (2 gr of Agarose dissolved in 100 ml 1X TAE buffer) to verify the 
absence of primer-dimers.  
The quantity of PCR product was measured with Thermo Scientific Nano Drop 
2000 spectrophotometer. The sample was opportunely diluted, dried for 15-20 
minutes and sent to BMR Genomics (spin-off of the University of Padua) where 
Sanger Sequencing was performed. 
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Collection of human plasma from adrenal veins and inferior cava 
 
 
 Adrenal Vein Sampling (AVS) is currently performed at our centre by 
an interdisciplinary team with extensive expertise in this field. After an hour of 
supine rest of the patient and correction of hypokalaemia, if present, blood was 
obtained from the two adrenal veins (right and left side) and inferior vena cava. 
Blood samples were collected in EDTA tubes and kept at 4C until measurements 
of cortisol and aldosterone. The cannulation was considered successful when 
selectivity index (Cortisol adrenal vein/ Cortisol inferior adrenal vein) was ≥ 1.1; 
lateralization index ≥ 2 ([A / C ] adrenal vein / [A / C ] adrenal vein contralateral) 
indicated lateralized excess aldosterone production (Rossi GP et Al 2001). 
 
 
 
Circulating DNA (ct-DNA) extraction from plasma of APA patients 
 
Blood obtained from the adrenal veins and inferior vena cava was first 
centrifuged at 3300 RPM for 15 minutes at 4C and then centrifuged again at 
16,000 RPM for 10 minutes at 4 C to remove cellular debris. Ct-DNA was 
extracted from 1ml of plasma using Qiamp DNA blood mini kit (Qiagen, Hilden, 
Germany) according to manufacture instructions. Cf-DNA was eluted in 30 ul of 
elution buffer. 
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Plasma DNA concentration and integrity index 
 
 
Since ct-DNA levels were too low to be measured with Nano drop 2000 
spectrophotometer we used a PCR based approach for ct-DNA measurement. 
Genomic DNA ranging from 10 ng/ul to 0.0016 ng/ul dilutions was used to build 
a PCR standard curve. The absolute concentration of ct-DNA was calculated 
using the standard curve. 
The same curve was also used to calculate the integrity index (DII), defined as 
ratio of longer (400 bp) to shorter amplicons (200bp) generated at the end of Q-
PCR.  DII ≥ 1.0 was assumed to denote cf-DNA integrity. The specific primers to 
perform such Q-PCR are reported in Figure 17.  
 
	  
	  
Gene	   Amplicon	  
lengths	  
Forward	  primer	   Reverse	  primer	  
KCNJ5	   (G151R,	  
L168R)	  
400	  bp	   TCAGGTTGACGCCGCTGT	  	  
	  
GAGAGATAGAATACATTACTGATGTGTGGAT	  
KCNJ5	  G151R	   200	  bp	   TCAGGTTGACGCCGCTGT	  	  
	  
TTCGTAGCCGTTCTGCTGC	  
KCNJ5	  L168R	   200	  bp	   TCAGGTTGACGCCGCTGT	  	  
	  
TCTATAAATGGACACCGATGGGTAGT	  
	  
Figure	  17:	  Primer	  design	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High resolution melting analysis (HRM) 
 
 
 
High resolution melting analysis (HRM) is a powerful technique that 
allows detection of mutations, polymorphisms and epigenetic differences in 
double-stranded DNA samples. HRM provides post-PCR analysis that 
characterizes DNA samples on the basis of the dissociative behavior (dsDNA-
ssDNA) with increasing temperature. The classic Q-PCR is first necessary to 
amplify the DNA region in which the mutation of interest takes place. Once PCR 
has ended, HRM analysis can begin. 
HRM process simply consists in a precise warming of the DNA amplicon from 
around 50˚C up to around 95˚C (an increase of 0.2 ˚C or 0.3 ˚C per seconds is 
usually used). At some point during this process, the melting temperature of the 
amplicon is reached and the two DNA strands separate or “melt” apart. The 
melting curve is produced by measuring the fluorescence of the amplification in 
relation to the temperature increase. The fluorescence values decrease with 
increasing temperature (dsDNA to ssDNA). To view the Tm, the negative 
derivative of the temperature is plotted in the pre-melt region where the values of 
fluorescence are 100% because the DNA is double stranded. Data analysis allows 
identification of homozygous and heterozygous samples and discrimination into 
different clusters. Hence, HRM can be considered one the most relevant next-
generation PCR applications.  
High resolution melting assays require a real-time PCR detection system with 
excellent thermal stability and HRM-dedicated software. HRM analysis was 
performed in our laboratory using CFX96 Touch Real-Time PCR machine 
additioned with specific software for Processing Melt Curve Data. This software 
allows a quick analysis of the data sets obtained from PCR and identification of 
DNA sequences based on their composition, length, GC content and strand 
complementarity. 
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Protocol for PCR and HRM analysis 
 
 
PCR amplifications were carried out in a reaction final volume of 10 ul. 
Each PCR reaction mixture was composed of 6.25 ul of PCR mix ( SsoFast™ Eva 
Green® Super mix) 0.75 ul of each primers (300nm/ul) 2.25 ul of DNA with final 
concentration of 2ng/ul. Melting curves were obtained by increasing the 
temperature from 65 °C to 95°C with a ramping of 0.3 °C for 10 seconds for 
L168R region and 0.3°C for 5 seconds for G151R. This approach was used to 
evaluate the different melting temperature (Tm) of wild type and mutated 
heteroduplexes of circulating DNA that are generates at the end of Q-PCR to 
pinpoint the difference between the different clusters generates from normalized 
melting curves. Wild type and mutated tissue of the corresponding plasma patients 
were used as controls. 
 
 
Statistical Analysis  
 
 
Results about concentrations of cf-DNA were expressed as mean.  
Integrity Index differences between groups were analyzed by t-test and, for 
multiple group comparison, by one-way ANOVA. The differences were 
considered to be significant at p < 0.05. Statistical analyses were performed using 
Graph pad/prism 5 for Windows software (Graph pad Software, La Jolla, 
California, USA; www.graphpad.com). 
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Results	  
 
 
 
Identification of KCNJ5 mutations in the APA tissue with Taq-man 
probe based technique 
 
	  
We first assessed the specificity of TAQ-MAN probes designed to detect 
L168R and G151R mutations in KCNJ5 gene by performing a gradient curve 
from 66°C o 55°C. This step is preliminary to Q-PCR and fundamental to 
evaluate the best annealing temperature (Ta) of the primer and the probe during 
the Q-PCR reaction. The reporter probes HEX and TEXAS RED were used for 
L168R and G151R regions, whereas FAM was used for wild type one. Because a 
synonymous mutation characterized by substitution of A with C was found for 
G151R mutation, we designed an additional probe that covers this mutated region. 
 
 
           	  
                                       
                      	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  18:	  Amplification	  curve	  in	  Q-­‐PCR	  for	  L168R	  mutated	  region	  (T/G)	  
 
 
FAM 
Texas Red 
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  Figure	  19:	  Amplification	  curve	  in	  Q-­‐PCR	  L168R	  mutated	  region	  (T/G)	  
  
 
 
We found that the annealing temperatures for the best discrimination of L168 
mutated region are: 62.0°C for FAM/TEXAS RED and 59.3°C for FAM/HEX 
(Figures 18 and 19). The annealing temperatures for the best discrimination of 
G151R mutated region are: 57.0°C for FAM/TEXAS RED and 62.0°C for 
FAM/HEX (Figures 18 and 19). 
 
 
 
 
 
 
 
 
 
 
FAM 
HEX 
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  Figure	  20:	  Amplification	  curve	  in	  Q-­‐PCR	  G151R	  mutated	  region	  (A/G)	  
	  
 
 
 
           
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  21:	  Amplification	  curve	  in	  Q-­‐PCR	  G151R	  mutated	  region	  (A/G)	  
 
 
 
 
 
FAM 
Texas Red 
FAM 
HEX 
 55 
 
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
 
 
                   
    
                           	  	  	  	  	  	  	  Figure	  22:	  Amplification	  curve	  in	  Q-­‐PCR	  G151R	  mutated	  region(C/G)	  
 
 
 
The best annealing temperatures for the synonymous mutation were 59.4°C and 
60.0°C (Figure 22). After establishing that each probe can discriminate between 
mutation and wild type, an additional experiment was performed to evaluate if the 
two probes designed for G151R mutated region interfere between them. For this 
experiment, both mutated probes (A/G, C/G) were loaded in the same well. 
 
 
 
 
 
 
 
 
 
FAM 
Texas Red 
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Figure	  23:	  Amplification	  curve	  in	  Q-­‐PCR	  G151R	  mutated	  region	  (C/A)	  
 
 
 
 
 
Figure	  24:	  Threshold	  cycle	  (Ct)	  of	  amplification	  	  
 
 
 
In a sample with synonymous mutation, the lack of interference between the 
probes was demonstrated by the amplification of only Texas Red, i.e. the probe 
that recognized base C. No amplification was observed for HEX. 
 
 
 
FAM 
Texas Red 
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Figure	  25	  Amplification	  curve	  in	  Q-­‐PCR	  G151R	  mutated	  region	  (A/C)	  
	  
 
 
 
Figure	  26:	  Threshold	  cycle	  (Ct)	  of	  amplification	  curve	  
	  
 
 
For mutated Taq-Man probe in HEX that recognized base A instead than C, the 
result in Figure 26 shows no amplification for TEXAS RED as expected.  
 
 
 
 
 
FAM 
HEX 
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Allelic discrimination 
 
 
At the end of entire cycle of Q-PCR with TAQMAN probes, genotypes are 
assigned by analyzing the amplification plots generated for each allele-specific, as 
described in detail in Material and Methods. The heterozygote population was 
showed with triangle and the WT population with red circle. These results show 
the clear difference about the two examined populations, with the first plot for 
G151R wild type and the mutated one (Figure 27) and the second one for L168R 
(Figure 28). 
 
 
Figure	  27:	  Allelic	  discrimination	  on	  for	  G151R	  
 
Figure	  28:	  Allelic	  discrimination	  for	  L168R	  
Positive Control 
Negative Control 
Negative Control 
Positive Control 
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Validation of new Taq--man based technique with Sanger Sequencing 
 
 
The results obtained with Taq-man probe were compared to those obtained 
with Sanger sequencing used as the gold standard method (Figure 29). Each 
mutation found with Taq-Man probes was detected with Sanger, and all mutations 
revealed with Sanger were found with Taq-man probes. Hence, these results 
showed high specificity and sensitivity of the probes designed in our laboratory 
and then suggests that they could be used for detecting KCNJ5 mutations. 
 
Figure 29 
 
G151R A/G 
 
 Synonymous mutation G151R C/G 
 
L168R G/T 
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Cell-free DNA isolation from plasma of Adrenal Vein Sampling  
 
In order to test the hypothesis that KCNJ5 gene mutations can be detected 
in cell-free nucleic acids that are released in the adrenal vein blood, we first 
evaluated the feasibility of isolating cf-DNA from AVS plasma. Then, we 
quantified cf-DNA and evaluated fragmentation index to investigate the 
mechanism (apoptosis or necrosis) by which cf-DNA is released from APA cells. 
Finally, we applied the Taq-man probe based technique to cf-DNA to detect 
KCNJ5 mutations.  
The first step was identification of the best operative procedure to isolate 
cf-DNA (Figure 30).  
 
 
  
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  30:	  Preanalytical	  conditions	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To identify the starting volume of plasma needed to isolate cf-DNA, various 
amounts of plasma volume, ranging from 250 ul to 1000 ul, were used. Figure 31 
shows 2% agarose gel where four different Q-PCR products of KCNJ5 gene 
expression were loaded. We obtained the best result from 1 ml plasma, as shown 
in lane 1. 
 
 
 
 
 
 
 
                          
 
	  
Figure	  31:	  2%	  Agarose	  gel	  with	  cf-­‐DNA	  extracted	  from	  different	  amounts	  of	  plasma	  	  
 
 
 
 
 
 
 
1 2 3 4 
1  cf-DNA from 1ml of plasma 
2  cf-DNA from 500 ul of plasma 
3  cf-DNA from 250 ul of plasma 
4 DNA from Buffy coat 
5 
5  H20 
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Calibration line for quantification of G151R 200pb fragment  
 
 
After confirming the expression of KCNJ5 gene in cf-DNA extracted from 
plasma obtained during AVS sample and verifying the product of PCR on agarose 
gel, we measured the concentration of cf-DNA with Q-PCR absolute 
quantification. Figure 32 shows the amplification curve for G151R region that 
produces amplicon of 200 bp, whereas the calibration line and the Ct value for 
each standard (corresponding to known concentrations of genomic DNA extracted 
from buffy coat) are shown in Figure 34. The dilutions were made from 10 ng/ul 
to 0.016 ng/ul. All samples were loaded in duplicate. 
 
 
 
 
 
 
Figure	  32:	  	  Amplification	  Curve	  of	  diluted	  genomic	  DNA	  from	  10	  to	  0.016	  ng/ul	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Figure	  33:	  	  Calibration	  line	  of	  diluted	  genomic	  DNA	  from	  10	  to	  0.016	  10ng/ul	  
 
 
 
 
 
Figure	  34:	  Ct	  value	  of	  standard	  dilution	  from	  10ng/ul	  to	  0.016	  of	  genomic	  DNA	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Calibration line for quantification of L168R 200 bp fragment  
 
 
Similar experiments were made for L168R 200 bp fragments. Below are 
reported the amplification curve for L168R region that produces 200 bp amplicon 
(Figure 35), the calibration line (Figure 36) and the value of Ct of each standard 
corresponding to genomic DNA extracted from buffy coat. The dilutions are made 
from 10 ng/ul to 0.016 ng/ul. All samples were loaded in duplicate. 
 
 
Figure	  35:	  	  Amplification	  Curve	  of	  diluted	  genomic	  DNA	  from	  10	  to	  0.016	  ng/ul	  	  
	  
	  
Figure	  36:	  	  Calibration	  line	  of	  diluted	  genomic	  DNA	  from	  10	  to	  0.016	  10ng/ul	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Figure	  37:	  Ct	  value	  of	  diluted	  standard	  genomic	  DNA	  (Std)	  from	  10	  to	  0.016	  ng/ul	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Calibration line for quantification of 400 bp fragment  
 
Similar Experiments were similarly made for 400 bp fragment, using the 
dilutions from 10 ng/ul to 0.016 ng/ul and loading the samples in duplicate. 
 
	  
	  
	  
Figure	  38:	  Amplification	  Curve	  of	  diluted	  genomic	  DNA	  from	  10	  to	  0.016	  ng/ul	  
	  
	  
	  
Figure	  39:	  	  Calibration	  line	  of	  diluted	  genomic	  DNA	  from	  10	  to	  0.016	  10ng/ul	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Figure	  40:	  Ct	  value	  of	  diluted	  standard	  genomic	  DNA	  (Std)	  from	  10	  to	  0.016	  ng/ul	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Absolute quantification of circulating DNA  
 
 
We calculated the absolute concentration of cf-DNAs extracted from 
inferior vena cava, right and left adrenal vein plasma collected during AVS.  
Plasma from peripheral blood of the patients undergoing AVS and plasma isolated 
from patients suffering with stomach cancer were used as positive controls. The 
table (Figure 41) below shows the absolute concentration values for each sample 
expressed as mean (ng/ul). 
	  
	  
Cf-­‐DNA	  	   Number	  of	  patients	   Concentration	  	  mean	  
ng/ul	  
	  Stomach	  cancer	   3	   	  7.15	  
Peripheral	  blood	   12	   0.68	  
	  Left	  Plasma	  (L)	   12	   0.46	  
Right	  plasma	  (R)	   12	   0.37	  
Cava	  Vein	   12	   0.76	  
	  
	  
Figure	  41:	  Concentration	  values	  of	  cf-­‐DNA	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Evaluation of fragmentation through Integrity index 
 
 
The integrity index was calculated as reported in detail in Material and 
Methods, starting from the concentration of each amplicon generates at the end of 
Q-PCR. In particular each integrity index (DII) was calculated as the ratio of 
longer (400bp) to shorter amplicons (200bp). In the bar graph below (Figure 42) 
are reported the results obtained from the samples whose concentrations are 
shown in Figure 41. DII was significantly lower in AVS than in cancer patients; 
thereby suggesting that apoptosis is the prevalent mechanism by which cf-DNA is 
released from the APA cells. 
	  
	  
	  
	  
	  
	  
 
	  
 
	  
	  
	  
	  
	  
	  
Figure	   42:	   The	   bar	   graph	   shows	   that	   DNA	   integrity	   index	   (DII)	   is	   higher	   for	   cf-­‐DNA	  
isolated	   from	   blood	   of	   stomach	   cancer	   patients	   than	   DII	   of	   blood	   peripheral	   plasma,	  
adrenal	   veins	   and	   inferior	   vena	   cava	   of	   APA	   patients.	   The	   major	   length	   of	   cf-­‐DNA	  
released	  from	  stomach	  cancer	  patients	  could	  be	  related	  to	  necrosis	  events	  that	  are	  less	  
evident	  in	  APA	  patients.	  
* 
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HRM analyses of DNA from APA tissue 
 
 
After measuring the length of ct-DNA isolated from AVS plasma and 
understanding that such ct-DNA could derive from apoptotic cells released from 
APA tissue, we evaluated the feasibility of pinpointing the mutations in KCNJ5 
gene using ct-DNA. We focused our attention on cf-DNA because AVS procedure 
is quite invasive and, therefore, the possibility of identifying gene mutations with 
cf-DNA seemed very attractive. 
To pursue this aim we exploited HRM-based technique that discriminates 
wild type and mutated heteroduplexes generated during the Q-PCR by analyzing 
melting temperature (Tm). At that temperature the strands of double DNA helix 
are separated, and heteroduplexes can be detected because of their specific 
denaturation melting temperature.  
The figures below show the results obtained from HRM for G151R 
mutation. To assess the best operative conditions, cf-DNA obtained from APA 
tissue was serially diluted (from 10 ng/ul to 0.016 ng/ul) to assess the sensitivity 
of HRM analyses (Figure 38). Correct dilution and purity of the sample are 
essential conditions to obtain optimal results from HRM. Figures 43 shows the 
melting peak for G151R mutation, whereas Figures 44 and 45 show the 
differences between normalized melting curves of mutated and wild type tissues, 
and the differences between different clusters within membership (Figure 42).  
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Figure	  43:	  Melting	  peak	  of	  G151R	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
 
 
Figure	  44:	  Normalized	  G151R	  melting	  curve	  	  
 
 
 
	  
Figure	  45:	  Normalized	  G151R	  melting	  curves	  give	  different	  clusters	  	  
  DNA from mutated tissue in C 
 DNA from mutated tissue in A 
 DNA from wild type  
  DNA from mutated tissue in C 
 DNA from mutated tissue in A 
 DNA from wild type  
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HRM analyses of circulating DNA from AVS sample 
 
 
After establishing that KCNJ5 mutations can be detected even using a very 
low concentration (0.4 ng/ul) of DNA, we isolated cf-DNA from the adrenal veins 
of a patient with somatic L168R mutation in the APA located in the left adrenal 
gland.  
The first step was performing a gradient curve to identify the best annealing 
temperature of primers for L168R region. The best results in terms of 
amplification were obtained with an annealing temperature of 53.0°C and 54.9°C. 
HRM analysis for L168R region was performed with 54.9°C annealing 
temperature and increasing temperature for melting analysis from 65°C to 95°C 
with ramping of 0.3°C for 10 seconds. Under these conditions we discriminated 
wild type from mutated circulating DNA. The same results were obtained from 
three different experiments. 
 
 
                           
	  
 
Figure	  46:	  Normalized	  L168R	  melting	  curve	  	  
 
	  
  Ct DNA from plasma of left side  
  Ct DNA from plasma right 
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  Ct DNA from wild type  
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Figure	  47:	  Normalized	  melting	  curves	  give	  different	  L168R	  clusters	  	  	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  48:	  Normalized	  melting	  curves	  give	  different	  G151R	  cluster	  with	  a	  percentage	  of	  
confidence	  of	  99%	  
 
 
One of these experiments was performed using 53°C as annealing temperature to 
evaluate the reproducibility of the experiments with a different temperature. 
Figure 49 shows that the result obtained with 53°C was similar to that obtained 
with 55°C, as reported in Figure 47. HRM analysis clearly showed the presence of 
L168R mutation in cf-DNA isolated from left adrenal vein and, therefore, from 
the APA side. The fact that cf-DNA isolated from left side clusters with the left 
adrenal tissue strongly supports the working hypothesis of this study that KCNJ5 
mutations can be detected not only in APA, but also in circulating blood. 
DNA from APA 
tissue 
  Ct DNA from plasma of left side  
  Ct DNA from plasma right 
side  
  Ct DNA from wild type  
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Figure 49: Normalized melting curves give different L168R cluster 	  
 
 
 
 
 
	  
	  
	  
  Ct DNA from plasma of left side  
  Ct DNA from plasma right 
side  
  Ct DNA from wild type  
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Discussion 
 
 
We developed in our laboratory a novel method based on Taq-man probes 
to detect somatic KCNJ5 mutations in the APA tissue. This novel method 
can be proposed as an alternative to Sanger sequencing, which is time 
consuming and expensive technique. When compared the results obtained 
from the Taq-man probes-based technique to those obtained from the gold 
standard Sanger technique, we did not find any misclassification of 
mutated and wild-type APAs, thereby providing evidence of diagnostic 
accuracy of the new method. 
The growing interest for the early diagnosis of mutated tumours, and the 
continuous research of a predictive method that supports AVS to subtype 
the two main forms of PA, prompted us to isolate cf-DNA from blood of 
the adrenal veins and detect KCNJ5 mutations in cf-DNA. By applying 
Taq-man probes-based technique and HRM analysis we were able to 
detect KCNJ5 mutation in cf-DNA isolated from the adrenal vein that 
drained blood from a mutated APA. In fact, HRM analysis clearly showed 
the presence of L168R mutation in cf-DNA isolated from left adrenal vein 
of one patient with an APA harboring L168R mutation in the left adrenal 
gland. The fact that cf-DNA isolated from left side clusters with the left 
adrenal tissue strongly supports the working hypothesis of this study that 
KCNJ5 mutations can be detected not only in APA, but also in circulating 
blood. Some methodologic aspects deserve interest because they were 
crucial for cf-DNA detection in plasma. For example, since cf-DNA levels 
are very low in blood under physiologic conditions or conditions 
associated with benign tumors, we modified our Taq-man protocol until 
reaching the best operative conditions that allowed us to analyze very tiny 
amounts of cf-DNA.  
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This study also suggests that the major mechanism by which cells release 
cf-DNA into the bloodstream is apoptosis. Cf-DNA isolated from plasma 
of adrenal veins and inferior vena cava was significantly lower than that 
found in peripheral blood of patients with stomach cancer. Progression of 
tumour and occurrence of metastases are factors usually associated with 
long circulating DNA fragments, which presumably derive from necrotic 
debris. In contrast, the release of fragments with minor length from 
apoptotic cells of wild type tissue and mutated APA could be related to the 
physiologic or pathophysiologic cellular turnover, respectively, not to 
necrotic death.  Cf-DNA fragments are usually generated at the end of 
apoptosis process in the cells, when the proteases and nuclear 
endonucleases act on chromatin generating fragments of about 200 bp. 
Apoptosis involves all tissues, even though to different extent, and 
therefore it is reasonable to contend occurrence of apoptosis also in the 
adrenal tissue. 
Hence, the new strategy based on Taq-man probes and HRM analysis 
could be useful not only for detecting gene mutations, but also to gain a 
deep insight into pathophysiologic mechanisms underlying the 
development of APA. 
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 Conclusions and perspectives 
 
 
 
The results of this study showed that somatic mutations in KCNJ5 gene 
could be detected in the APA tissue using highly specific TAQ-MAN probes. This 
approach developed in our laboratory avoids use of the time-consuming Sanger 
sequencing, and also allows detection of G151R and L168 mutations at the same 
time and in the same PCR sample. TAQ-MAN probes-based technique associated 
with HRM analyses seems a promising approach even for the detection of KCNJ5 
mutations in cf-DNA isolated from the adrenal vein that drains blood from the 
mutated APA, suggesting that KCNJ5 mutations may be revealed before 
adrenalectomy. Since APAs harboring KCNJ5 mutation were found to be 
associated with higher aldosterone levels than wild-type APAs, an early detection 
of the mutation could be useful to select patients to address to AVS. 
The relatively low integrity index of cf-DNA suggests that DNA is 
released from the APA cells that undergo apoptosis and, therefore, provides novel 
information on pathophysiology of the APA.  
Hence, these findings collectively would lay the foundations for the 
development of a strategy to pinpoint the mutations in KNJ5 gene. Furthermore, 
this strategy could be applied to detect KCNJ5 mutations involved in germline 
heterozygous mutations responsible for hereditary form of hyperaldosteronism 
(FH-3). 
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